CYBN cybin.com: Long-Term Debt to Capital Coefficient

Symbol and logo of brand Cybin (CYBN)

Cybin Inc. relies on patent protection for its exclusive anti-depressant formulas, which will enable the company to exercise pricing power over its drugs following certification. The business is investing in neurobiology and the development of smart delivery methods for modified molecules. This chart reflects the current share price of 0.20, underscoring the status of a recognized visionary that has received FDA confirmation of the breakthrough nature of its developments.

CYBN - cybin.com Long-Term Debt to Equity over the range 07/04/2022 - 01/05/2026

Comprehensive metric breakdowns and analytics for Cybin Inc (CYBN)

- price and consensus price forecast:
Quote Chart Cybin Corp|CYBN - Analyst Consensus Forecast
- market capitalization data:
Market Value Cybin Inc.|CYBN - Enterprise Value
- book capitalization data:
Book Value per Share Cybin|CYBN - Company Book Value|Market Value to Book Value cybin.com|CYBN - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Cybin Inc.|CYBN - Long-Term Debt to Capital|Short-Term Debt to Capital Cybin Corp|CYBN - Company Total Debt|Debt to Net Assets Ratio Cybin Inc.|CYBN - Company Long-Term Debt|Current Liabilities Cybin
Initial company analysis:cybin.com
Core merchandise of Cybin Inc

Cybin Inc. is investing in bioscreening automation and IT molecular modeling, which requires significant capital expenditures for the technology stack. When analyzing financial leverage via long-term debt, an investor assesses the ratio of liabilities with a maturity of over one year to equity to determine the extent of the company's reliance on borrowed funds and its overall solvency.

Competitors of Cybin Inc. (CYBN)

Long-Term Liabilities to Equity Alkermes PLC|Avadel Pharma (AVDL) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient atai (ATAI)|Long-Term Debt to Capital GHRS (GH Research PLC)|mindmed.co - Long-Term Debt to Capital|Long-Term Debt to Equity COMPASS Pathways (CMPS)|LBRX: Long-Term Debt to Capital Coefficient|DRUG (Bright Minds Biosciences Inc) - Long-Term Debt to Equity|Vanda (VNDA) - Long-Term Debt to Equity Ratio|ANRO (Alto Neuroscience, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital nrxpharma.com (NRXP)|Cingulate Inc. (CING) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient SILO (silopharma.com)|China Pharma Holdings, Inc. (CPHI) - Long-Term Debt to Equity|Clearmind Medicine, Inc. - Long-Term Liabilities to Equity|Long-Term Debt to Equity PBM (Psyence Biomedical Ltd.)|scisparc.com (SPRC) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio SEEL|Virpax Pharmaceuticals, Inc. (VRPX) - Long-Term Liabilities to Capital|Long-Term Debt to Capital KRTX